Barrett's esophagus secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 2: Line 2:
{{Barrett's esophagus}}
{{Barrett's esophagus}}


{{CMG}}; {{AE}}  
{{CMG}}; {{AE}}; {{AMK}}


==Overview==
==Overview==
Line 15: Line 15:
Recommendations:
Recommendations:


* Therapy with medications effective to treat GERD symptoms and to heal reflux esophagitis is strongly recommended.
* [[Therapy]] [[with]] [[medications]] [[effective]] [[to]] [[treat]] [[GERD]] [[symptoms]] [[and]] [[to]] [[heal]] [[reflux esophagitis]] [[is]] [[strongly]] [[recommended]].


* Do not attempt to eliminate acid exposure of the esophagus
* [[Do]] [[not]] [[attempt]] [[to]] [[eliminate]] [[acid]] [[exposure]] [[of]] [[the]] [[esophagus]]
# Use proton pump inhibitors in doses greater than once daily. There is no evidence that higher doses produce a risk reduction in cancer.
# [[Use]] [[proton pump inhibitors]] [[in]] [[doses]] [[greater]] [[than]] [[once]] [[daily]]. [[There]] [[is]] [[no]] [[evidence]] [[that]] [[higher]] [[doses]] [[produce]] [[a]] [[risk]] [[reduction]] [[in]] [[cancer]].
# Titrate proton pump inhibitors dose by esophageal pH monitoring.
# [[Titrate]] [[proton pump inhibitors]] [[dose]] [[by]] [[esophageal]] [[pH]] [[monitoring]].
# Antireflux surgery. This is not more effective than medical therpay.
# [[Anti-reflux]] [[surgery]]. [[This]] [[is]] [[not]] [[more]] [[effective]] [[than]] [[medical]] [[therpay]].
Risks and benefits of long-term PPI therapy should be discussed with the patients.
[[Risks]] [[and]] [[benefits]] [[of]] [[long-term]] [[PPI]] [[therapy]] [[should]] [[be]] [[discussed]] [[with]] [[the]] [[patients]].


* Do not use aspirin to prevent esophageal adenocarcinoma in the absence of other indications (e.g. cardiovascular risk factors). Although evidence suggests NSAIDs may decrease the incidence of esophageal cancer, it is not clear if benefits outweight the risks of using this medications.<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011  |pmid=21376940 |doi=10.1053/j.gastro.2011.01.030 |url=}}</ref>
* [[Do]] [[not]] [[use]] [[aspirin]] [[to]] [[prevent]] [[esophageal]] [[adenocarcinoma]] [[in]] [[the]] [[absence]] [[of]] [[other]] [[indications]] (e.g. [[cardiovascular]] [[risk factors]]). [[Although]] [[evidence]] [[suggests]] [[NSAIDs]] [[may]] [[decrease]] [[the]] [[incidence]] [[of]] [[esophageal]] [[cancer]], [[it]] [[is]] [[not]] [[clear]] [[if]] [[benefits]] [[outweight]] [[the]] [[risks]] [[of]] [[using]] [[this]] [[medications]].<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011  |pmid=21376940 |doi=10.1053/j.gastro.2011.01.030 |url=}}</ref>


==Secondary Prevention==
==Secondary Prevention==

Revision as of 18:55, 7 November 2017

Barrett's Esophagus Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Barrett's Esophagus from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Endoscopic Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Barrett's esophagus secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Barrett's esophagus secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Barrett's esophagus secondary prevention

CDC on Barrett's esophagus secondary prevention

Barrett's esophagus secondary prevention in the news

Blogs on Barrett's esophagus secondary prevention

Directions to Hospitals TreatingBarrett's esophagus

Risk calculators and risk factors for Barrett's esophagus secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Amresh Kumar MD [2]

Overview

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

Secondary prevention

Recommendations:

  1. Use proton pump inhibitors in doses greater than once daily. There is no evidence that higher doses produce a risk reduction in cancer.
  2. Titrate proton pump inhibitors dose by esophageal pH monitoring.
  3. Anti-reflux surgery. This is not more effective than medical therpay.

Risks and benefits of long-term PPI therapy should be discussed with the patients.

Secondary Prevention

  • There are no established measures for the secondary prevention of [disease name].

OR

  • Effective measures for the secondary prevention of [disease name] include:
    • [Strategy 1]
    • [Strategy 2]
    • [Strategy 3]

References

  1. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ (2011). "American Gastroenterological Association medical position statement on the management of Barrett's esophagus". Gastroenterology. 140 (3): 1084–91. doi:10.1053/j.gastro.2011.01.030. PMID 21376940.

Template:WH Template:WS